Inhibiting glucosylceramide synthase facilitates the radiosensitizing effects of vinorelbine in lung adenocarcinoma cells.

[1]  Helen H. W. Chen,et al.  Oral vinorelbine: a Better Choice for Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer , 2012 .

[2]  W. Su,et al.  Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells. , 2012, Biochemical pharmacology.

[3]  G. Videtic.  Locally advanced non–small cell lung cancer: What is the optimal concurrent chemoradiation regimen? , 2012, Cleveland Clinic Journal of Medicine.

[4]  K. Kaira,et al.  Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI). , 2012, International journal of radiation oncology, biology, physics.

[5]  Yee‐Shin Lin,et al.  Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr‐Abl inhibitor and cooperatively induces glycogen synthase kinase‐3‐regulated apoptosis , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  M. Provencio,et al.  Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. , 2011, Journal of thoracic disease.

[7]  Yee‐Shin Lin,et al.  Apoptotic Sphingolipid Ceramide in Cancer Therapy , 2011, Journal of lipids.

[8]  W. Curran,et al.  Combined modality therapy for stage III non-small-cell lung cancer. , 2010, Seminars in radiation oncology.

[9]  Jing Yi,et al.  Cancer cell killing via ROS: To increase or decrease, that is the question , 2008, Cancer biology & therapy.

[10]  J. Vermorken,et al.  Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro , 2008, BMC Cancer.

[11]  Joseph K Salama,et al.  The concurrent chemoradiation paradigm—general principles , 2007, Nature Clinical Practice Oncology.

[12]  M. Socinski,et al.  Combined modality therapy for stage III non-small cell lung cancer. , 2006, The oncologist.

[13]  Chiou-Feng Lin,et al.  Ceramide in apoptotic signaling and anticancer therapy. , 2006, Current medicinal chemistry.

[14]  R. Fietkau,et al.  Oral Vinorelbine and Cisplatin with Concomitant Radiotherapy in Stage III Non-Small Cell Lung Cancer (NSCLC): A Feasibility Study , 2006, Oncology Research and Treatment.

[15]  D. Galetta,et al.  Multimodality treatment of unresectable stage III non-small cell lung cancer: interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. , 2006, The Journal of thoracic and cardiovascular surgery.

[16]  S. Kurinna,et al.  Ceramide Promotes Apoptosis in Lung Cancer-Derived A549 Cells by a Mechanism Involving c-Jun NH2-Terminal Kinase , 2004, Cancer Research.

[17]  S. Clarke,et al.  Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. , 2004, International journal of radiation oncology, biology, physics.

[18]  R. Schmidt‐Ullrich.  Molecular targets in radiation oncology , 2003, Oncogene.

[19]  P. Ruvolo.  Intracellular signal transduction pathways activated by ceramide and its metabolites. , 2003, Pharmacological research.

[20]  T. Araki,et al.  Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. , 2003, Lung cancer.

[21]  H. Ichijo,et al.  Phosphorylation and Inactivation of Myeloid Cell Leukemia 1 by JNK in Response to Oxidative Stress* , 2002, The Journal of Biological Chemistry.

[22]  J. Usuda,et al.  Mechanism of vinorelbine-induced radiosensitization of human small cell lung cancer cells , 2002, Cancer Chemotherapy and Pharmacology.

[23]  J. Usuda,et al.  Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. , 2001, Lung cancer.

[24]  T Takahashi,et al.  ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis , 2001, EMBO reports.

[25]  A. Giuliano,et al.  Ceramide glycosylation potentiates cellular multidrug resistance , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  B. Hill,et al.  Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. , 2000, Cancer research.

[27]  W. Curran,et al.  Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .

[28]  T. Chambers,et al.  Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. , 2000, Experimental cell research.

[29]  J. Herndon,et al.  Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. , 1996, Journal of the National Cancer Institute.

[30]  M. Edelstein,et al.  Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. , 1996, Seminars in oncology.

[31]  K. Scotto,et al.  Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals , 1995, Cell.

[32]  B. Jeremic,et al.  Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  H. Burris,et al.  Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. , 1994, Seminars in oncology.

[34]  Y. Hannun,et al.  Programmed cell death induced by ceramide. , 1993, Science.

[35]  G. van Kaick,et al.  New aspects in the staging of lung cancer. Prospective validation of the international union against cancer TNM classification , 1992, Cancer.

[36]  H. Bartelink,et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.

[37]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[38]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[39]  A. Dueñas-González,et al.  Radiation Oncology BioMed Central Review Radiosensitizers in cervical cancer. Cisplatin and beyond , 2006 .